Vice-President, Business Development, IRICoR
T + 514 343.6647
F + 514 343.2165
Dr. Steven Klein is IRICoR’s VP, Business Development. With over 15 years of experience in a variety of fields, including oncology, vaccines, and CNS-related indications, Dr Klein bring an invaluable knowledge of the private sector and of private-public initiatives.
At IRICoR since 2011, he has successfully negotiated and managed agreements with a variety of private sector partners, including BMS, Merck, Pfizer, AstraZeneca, Domain Therapeutics, Encycle Therapeutics, Cyclenium Pharmaceuticals, and AmorChem, as well as IRICoR’s alliances with its CECR and academic partners, including MaRS Innovation, CCRM, Neomed, CDRD, and the Hospital for Sick Children. Dr. Klein also represented IRICoR in creating its recent spin-off companies ExCellThera and SpecificiT.
Prior to joining IRICoR, Dr. Klein held Business Development roles at Labopharm, BELLUS Health, Neurochem, and the Canadian Network for Vaccines and Immunotherapeutics (CANVAC) where he negotiated and concluded a wide range of licensing and co-development agreements, covering both products and technologies, with industry leaders such as Roche, GSK, Grunenthal, Sanofi Pasteur, Becton Dickinson, and Nippon Shinyaku.
Dr. Klein holds a B.Sc. (Honors) in Chemistry from Concordia University, a Ph.D. in Experimental Medicine from McGill University, and an MBA from Queen’s University.
Dr. Klein is a Board member of the Centre for the Commercialization of Antibodies and Biologics (CCAB), and has recently been asked to serve as a reviewer for the CIHR’s Commercialization committee in the upcoming Project Grant competition.